Literature DB >> 12111703

Stat3 enhances the growth of LNCaP human prostate cancer cells in intact and castrated male nude mice.

Fernando DeMiguel1, Soo Ok Lee, Wei Lou, Xiao Xiao, Beth R Pflug, Joel B Nelson, Allen C Gao.   

Abstract

BACKGROUND: Prostate cancer frequently progresses from an initial androgen dependence to androgen independence, rendering the only effective androgen ablation therapy useless. The mechanism underlying the androgen-independent progression is unknown. Stat3, a member of the family of signal transducers and activators of transcription, is activated in numerous cancers, including prostate. This study is to investigate the role of Stat3 activation in the growth of prostate cancer cells.
METHODS: A constitutively active Stat3 was ectopically expressed in androgen-sensitive LNCaP prostate cancer cells and resulting stable clones expressing activated Stat3 were isolated. The effect of Stat3 activation on LNCaP cell growth in response to androgen in vitro and in vivo was examined.
RESULTS: We show that the levels of activated Stat3 are associated with the progression of androgen-independent prostate cancer. Activation of Stat3 in androgen-sensitive LNCaP prostate cancer cells results in enhancement of tumor growth in both intact and castrated male nude mice and enhances androgen receptor-mediated prostate specific antigen expression.
CONCLUSIONS: These findings demonstrate that intracellular signaling mediated by Stat3 can enhance the growth of androgen-sensitive human LNCaP prostate cancer cells in both intact and castrated male nude mice. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12111703     DOI: 10.1002/pros.10110

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  19 in total

Review 1.  Mechanisms of persistent activation of the androgen receptor in CRPC: recent advances and future perspectives.

Authors:  Nagalakshmi Nadiminty; Allen C Gao
Journal:  World J Urol       Date:  2011-10-19       Impact factor: 4.226

2.  Genome-wide CRISPR screen identifies HNRNPL as a prostate cancer dependency regulating RNA splicing.

Authors:  Teng Fei; Yiwen Chen; Tengfei Xiao; Wei Li; Laura Cato; Peng Zhang; Maura B Cotter; Michaela Bowden; Rosina T Lis; Shuang G Zhao; Qiu Wu; Felix Y Feng; Massimo Loda; Housheng Hansen He; X Shirley Liu; Myles Brown
Journal:  Proc Natl Acad Sci U S A       Date:  2017-06-13       Impact factor: 11.205

3.  Morusin induces cell death through inactivating STAT3 signaling in prostate cancer cells.

Authors:  Sung-Lyul Lim; Sang-Yoon Park; Sukmin Kang; Dain Park; Sung-Hoon Kim; Jae-Young Um; Hyeung-Jin Jang; Jun-Hee Lee; Chul-Ho Jeong; Jung-Hee Jang; Kwang Seok Ahn; Seok-Geun Lee
Journal:  Am J Cancer Res       Date:  2014-12-15       Impact factor: 6.166

4.  Niclosamide suppresses cell migration and invasion in enzalutamide resistant prostate cancer cells via Stat3-AR axis inhibition.

Authors:  Chengfei Liu; Wei Lou; Cameron Armstrong; Yezi Zhu; Christopher P Evans; Allen C Gao
Journal:  Prostate       Date:  2015-05-13       Impact factor: 4.104

5.  Aberrant activation of the androgen receptor by NF-kappaB2/p52 in prostate cancer cells.

Authors:  Nagalakshmi Nadiminty; Wei Lou; Meng Sun; Jun Chen; Jiao Yue; Hsing-Jien Kung; Christopher P Evans; Qinghua Zhou; Allen C Gao
Journal:  Cancer Res       Date:  2010-04-13       Impact factor: 12.701

6.  Inhibition of Stat3 activation by sanguinarine suppresses prostate cancer cell growth and invasion.

Authors:  Meng Sun; Chengfei Liu; Nagalakshmi Nadiminty; Wei Lou; Yezi Zhu; Joy Yang; Christopher P Evans; Qinghua Zhou; Allen C Gao
Journal:  Prostate       Date:  2011-05-02       Impact factor: 4.104

7.  Constitutively activated Stat3 induces tumorigenesis and enhances cell motility of prostate epithelial cells through integrin beta 6.

Authors:  Janeen Azare; Kenneth Leslie; Hikmat Al-Ahmadie; William Gerald; Paul H Weinreb; Shelia M Violette; Jacqueline Bromberg
Journal:  Mol Cell Biol       Date:  2007-04-16       Impact factor: 4.272

8.  PrLZ protects prostate cancer cells from apoptosis induced by androgen deprivation via the activation of Stat3/Bcl-2 pathway.

Authors:  Dong Zhang; Dalin He; Yan Xue; Ruoxiang Wang; Kaijie Wu; Hongjun Xie; Jin Zeng; Xinyang Wang; Haiyen E Zhau; Leland W K Chung; Luke S Chang; Lei Li
Journal:  Cancer Res       Date:  2011-03-08       Impact factor: 12.701

9.  Andrographolide targets androgen receptor pathway in castration-resistant prostate cancer.

Authors:  Chengfei Liu; Nagalakshmi Nadiminty; Ramakumar Tummala; Jae Yeon Chun; Wei Lou; Yezi Zhu; Meng Sun; Christopher P Evans; Qinghua Zhou; Allen C Gao
Journal:  Genes Cancer       Date:  2011-02

10.  Inhibition of constitutively active Stat3 reverses enzalutamide resistance in LNCaP derivative prostate cancer cells.

Authors:  Chengfei Liu; Yezi Zhu; Wei Lou; Yuanyuan Cui; Christopher P Evans; Allen C Gao
Journal:  Prostate       Date:  2013-10-16       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.